Search results below include Worst Pills, Best Pills Newsletter Articles where your
selected drug is a secondary subject of discussion.
February 2023
Learn about a new study showing that patients taking rosuvastatin (CRESTOR, EZALLOR SPRINKLE) had a higher risk of proteinuria (abnormal levels of protein in the urine) and hematuria (blood in the urine) than those taking another statin, atorvastatin (LIPITOR).
February 2016
Statins have long been a mainstay of treatment for patients with high LDL (“bad” cholesterol) and cardiovascular disease. In this article, we explain why you should avoid combining a nonstatin cholesterol-lowering dug with a statin.
March 2014
Dr. Sidney Wolfe, founding editor of Worst Pills, Best Pills News, concludes that “there is pathological lack of corporate integrity in many drug companies.” Read this article to find out why.
August 2013
A new study casts serious doubt on the usefulness of long-popular niacin products to treat or prevent cardiovascular disease.
June 2011
This article lists 355 drugs with names that are often confused with similar-sounding drug names. Find out what you can do to prevent getting the wrong drug.
May 2008
This article lists more than 60 prescription drugs that can interact with calcium channel blocking drugs such as amlodipine (NORVASC),diltiazem (CARDIZEM, DILACOR XR TIAZAC)or nifedipine (PROCARDIA)to either cause toxicity or to lessen the effectiveness of the calcium channel blocking drugs. Included in the lists are a number of drugs that we list in Worst Pills, Best Pills as DO NOT USE or LIMITED USE drugs. The article also explains the different kinds of toxicity that can ensue from these interactions.
March 2008
Find out why Worst Pills warned against the use of VYTORIN more than three years ago. Also, learn about new evidence showing that despite the fact that this drug lowers cholesterol, there is no evidence that it prevents heart attacks or strokes (though massive misleading advertising would have you believe otherwise).
February 2008
The article discusses the adverse drug interactions between either of two widely-prescribed macrolide antibiotics, erythromycin (as in ERYTHROCIN) and clarithromycin (BIAXIN)and more than 40 other drugs that are listed in a table in the article. It also describes the nature of the adverse interactions that can occur.
May 2007
Not only does this study find that consumer drug ads are not educational, it also says that the ads may oversell the benefits of the drugs and could put the public health in danger. For example, of the 24 drugs included in this advertising study, seven are listed as Do Not Use in Worst Pills, Best Pills publications. You should not rely on direct-to-consumer television advertisements as a source of drug information.
January 2006
We have asked the Food and Drug Administration (FDA) to add black box warnings to the professional product labels, or package inserts, for the erectile dysfunction drugs sildenafil (VIAGRA), tadalafil (CIALIS), and vardenafil (LEVITRA). The warnings would alert prescribers to the possibility of irreversible vision loss with the use of these drugs.
July 2005
Further evidence that Crestor causes uniquely high rates of muscle and kidney damage
December 2004
We are concerned about any new drug but are particularly concerned about the use of ZETIA together with statins.
May 2004
Aspirin is the preferred preventive treatment for those who have already had a heart attack (secondary prevention), at least for the majority of people who are not intolerant to aspirin. However, the lack of evidence of an aspirin benefit in the primary prevention of heart attack is clearly outweighed by the increased risk of bleeding from aspirin, and you should not use aspirin for the primary prevention of heart attacks.
April 2004
According to a supplement put out by Advertising Age in March entitled Fact Pack 2004 Edition, with additional information taken from Ad Age’s web site, the pharmaceutical industry continues to be quite adept at maintaining its place among the leading advertisers. Four of the top 25 U.S. advertisers, in terms of spending in this country during 2002, were drug companies. The article urges that you do not waste your time looking at or listening to prescription (or over-the-counter) drug ads.
October 2003
Rosuvastatin (CRESTOR) became the sixth cholesterol lowering "statin" drug on the U.S. There is no medical reason for you to be taking rosuvastatin when there are three safer and more effective statins, in terms of reducing cardiovascular events, on the market.
September 2002
Several new safety labeling changes have been required by the Food and Drug Administration (FDA) for the widely used anticoagulant drug warfarin (COUMADIN). These changes to the drug’s professional product labeling, or “package insert,” were made in May 2002. The article discusses the changes.
August 2002
The Food and Drug Administration (FDA) announced on June 18, 2002, the results of a national study to determine the extent of distribution and the quality of unregulated written drug information, known as “patient information leaflets” (PILs), produced by commercial information vendors to be disseminated by pharmacists to drug consumers when prescriptions are filled. The study’s results were appalling.
Login
Subscribe